Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16937258 | 0.87 | CYP1A2 (0.39) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL19272979 | 0.86 | CYP1A2 (0.38) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL20738982 | 0.84 | CYP1A2 (0.37) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL9545078 | 0.83 | CYP1A2 (0.46) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL29955357 | 0.83 | L3MBTL1 (0.38) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL29110119 | 0.80 | CYP2C19 (0.45) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL29110116 | 0.80 | CYP2C19 (0.45) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL764718 | 0.79 | ALDH1A1 (0.36) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL939579 | 0.79 | CYP1A2 (0.35) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL14507097 | 0.79 | CYP2C19 (0.38) | CYP2C19CYP1A2CYP2D6CYP2C9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103951663-B | Containing replacing the pyrazole amide of 1,3,4-thiadiazoles thioether and pyrazole imine analog derivative and preparation method and application | 贵州大学 | 2016-08-17 | — | — | CN | claimed |
| WO-2024150100-A1 | NEW PROCESS FOR MANUFACTURING OF 3-HALOMETHYL-SUBSTITUTED 1-METHYL-1H-PYRAZOLE-4-CARBONITRILES AND OF DERIVATIVES THEREOF, AND INTERMEDIATES THEREFORE | FLUORINNOVATION L.L.C-FZ (AE) | 2024-07-18 | — | — | WO | disclosed |
| CN-111943900-B | Isoxazoline derivatives and their use in agriculture | 宁夏苏融达化工有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-6063734-A | AGRICULTURAL CHEMICALS, AGENTS FOR PREVENTING ATTACHMENT OF AQUATIC ORGANISMS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-16 | — | — | US | disclosed |
| CN-1216530-A | Ethylene derivatives and pesticides containing the same | NISSAN CHEMICAL IND LTD (JP) | 1999-05-12 | — | — | CN | disclosed |
| EP-0913392-A1 | ETHYLENE DERIVATIVES AND PEST CONTROLLING AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-05-06 | — | — | EP | disclosed |
| EP-0623113-B1 | PYRAZOLE CARBOXANILIDE FUNGICIDES | MONSANTO CO (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0644879-A1 | HERBICIDAL PYRAZOLE-(THIO)-CARBOXAMIDES | RHONE POULENC AGRICULTURE LTD. (GB) | 1995-03-29 | — | — | EP | disclosed |
| EP-0623113-A1 | PYRAZOLE CARBOXANILIDE FUNGICIDES. | MONSANTO CO (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993025535-A1 | HERBICIDAL PYRAZOLE-(THIO)-CARBOXAMIDES | RHONE POULENC AGRICULTURE LTD. (GB) | 1993-12-23 | — | — | WO | disclosed |
| CN-1078234-A | Pyrazole carboxanilide fungicide | MONSANTO CO (US) | 1993-11-10 | — | — | CN | disclosed |
| US-5223526-A | For plants | MONSANTO COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1993011117-A1 | PYRAZOLE CARBOXANILIDE FUNGICIDES | MONSANTO COMPANY (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | CYP2C19 948/4885CYP1A2 395/4885CYP2D6 515/4885 |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | CYP2C19 169/4885CYP1A2 272/4885CYP2D6 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.